Table 3.
Factors potentially associated with acute kidney injury in patients with high-dose polymyxin B therapy.
| Variable Median (IQR) or No. (%) |
Univariate Analysis | Multivariable Analysis | |||
|---|---|---|---|---|---|
| No AKI (n = 18) |
AKI (n = 25) |
p Value | Adjusted OR (95% CI) | p Value | |
| Demographics and Infection Characteristics | |||||
| Age (years) | 55 (27–66) | 54 (36–66) | 0.89 | ||
| Male gender | 12 (66.7) | 18 (72.0) | 0.71 | ||
| Age-adjusted Charlson comorbidity index | 3 (1–6) | 3 (0–4) | 0.21 | ||
| APACHE II at infection onset | 16 (12–22) | 19 (11–21) | 0.74 | ||
| APACHE II at high-dose PMB initiation | 17 (12–22) | 22 (15–24) | 0.22 | ||
| Renal insufficiency at high-dose PMB initiation | 5 (27.8) | 3 (12.0) | 0.20 | ||
| In-hospital 30-day all-cause mortality | 3 (16.7) | 5 (20.0) | 0.78 | ||
| Details of PMB dosing prior to time at risk a | |||||
| Duration of PMB (days) | 12 (7–20) | 12 (8–14) | 0.68 | ||
| Overall average daily PMB dose (IU/kg) | 30 273 (29 126–33 333) | 33 708 (30 000–37 037) | 0.04 | 1.01 (1.00–1.02) | 0.04 |
| Overall cumulative PMB (MIU) | 20 (12–30) | 23 (16–27) | 0.95 | ||
| Use of combination therapy | 17 (94.4) | 23 (92.0) | 0.76 | ||
| Use of concomitant nephrotoxins | |||||
| Diuretics | 5 (27.8) | 12 (48.0) | 0.19 | ||
| Vancomycin | 16 (88.9) | 24 (96.0) | 0.39 | ||
| Aminoglycosides | 7 (38.9) | 14 (56.0) | 0.27 | ||
| Intravenous contrast | 4 (22.2) | 11 (44.0) | 0.15 | ||
| Total number of nephrotoxins | 2 (1–2) | 3 (2–3) | 0.04 | 2.14 (1.03–4.45) | 0.04 |
a Time at risk was defined as the time from admission to development of AKI for patients who developed AKI due to high-dose PMB, and the time from admission to death or discharge for those who did not develop AKI due to high-dose PMB; NOTE: IU, international units; MIU, million international units; PMB, polymyxin B.